Adjusted* beta-coefficient (β) with 95% CI, trend p value, with Akaike information criterion (AIC), for the relation between butadiene or styrene ppm-years (including person-time with zero monomer exposure), lagged 0, 10 or 20 years, and lymphohaematopoietic cancers (LHC)
| Monomer, Form of LHC, lag period (years) | β | 95% CI | Trend p value | AIC |
| I. Butadiene | ||||
| All leukaemia | ||||
| 0 | 2.55×10−4 | 0.52 to 4.57×10−4 | 0.014 | 2384 |
| 10 | 2.58×10−4 | 0.38 to 4.78×10−4 | 0.022 | 2337 |
| 20 | 2.63×10−4 | −0.05 to 5.31×10−4 | 0.055 | 2120 |
| Lymphoid leukaemia | ||||
| 0 | 3.81×10−4 | 1.05 to 6.58×10−4 | 0.007 | 933 |
| 10 | 3.73×10−4 | 0.78 to 6.68×10−4 | 0.013 | 933 |
| 20 | 3.00×10−4 | −0.70 to 6.69×10−4 | 0.112 | 868 |
| Myeloid leukaemia | ||||
| 0 | 1.09×10−4 | −3.01 to 5.18×10−4 | 0.602 | 1235 |
| 10 | 1.16×10−4 | −3.33 to 5.66×10−4 | 0.612 | 1189 |
| 20 | 2.11×10−4 | −2.90 to 7.11×10−4 | 0.410 | 1054 |
| Acute myeloid leukaemia | ||||
| 0 | −1.08×10−4 | −9.12 to 6.97×10−4 | 0.793 | 746 |
| 10 | −0.72×10−4 | −8.54 to 7.10×10−4 | 0.857 | 724 |
| 20 | −0.14×10−4 | −8.85 to 8.57×10−4 | 0.975 | 641 |
| Non-Hodgkin’s lymphoma | ||||
| 0 | 0.26×10−4 | −3.73 to 4.25×10−4 | 0.898 | 1976 |
| 10 | 1.10×10−5 | −43.61 to 45.80×10−5 | 0.962 | 1973 |
| 20 | −6.18×10−5 | −67.04 to 54.67×10−5 | 0.842 | 1876 |
| Multiple myeloma | ||||
| 0 | −0.82×10−4 | −5.08 to 3.45×10−4 | 0.707 | 1056 |
| 10 | −7.54×10−5 | −52.81 to 37.74×10−5 | 0.744 | 1054 |
| 20 | −9.77×10−5 | −64.26 to 44.73×10−5 | 0.725 | 955 |
| B-cell malignancy | ||||
| 0 | 1.15×10−4 | −0.75 to 3.05×10−4 | 0.237 | 3785 |
| 10 | 1.13×10−4 | −0.95 to 3.21×10−4 | 0.287 | 3779 |
| 20 | 0.73×10−4 | −1.95 to 3.40×10−4 | 0.595 | 3517 |
| II. Styrene | ||||
| Leukaemia | ||||
| 0 | 1.04×10−3 | −0.26 to 2.33×10−3 | 0.116 | 2386 |
| 10 | 1.03×10−3 | −0.38 to 2.45×10−3 | 0.153 | 2339 |
| 20 | 0.96×10−3 | −0.82 to 2.74×10−3 | 0.289 | 2122 |
| Lymphoid leukaemia | ||||
| 0 | 1.63×10−3 | 0.03 to 3.23×10−3 | 0.046 | 936 |
| 10 | 1.67×10−3 | −0.06 to 3.40×10−3 | 0.058 | 934 |
| 20 | 1.43×10−3 | −0.74 to 3.60×10−3 | 0.197 | 869 |
| Myeloid leukaemia | ||||
| 0 | −2.36×10−4 | −32.20 to 27.48×10−4 | 0.877 | 1235 |
| 10 | −4.37×10−4 | −39.04 to 30.30×10−4 | 0.805 | 1189 |
| 20 | −3.53×10−4 | −46.45 to 39.40×10−4 | 0.872 | 1054 |
| Acute myeloid leukaemia | ||||
| 0 | −6.23×10−4 | −51.03 to 38.56×10−4 | 0.785 | 746 |
| 10 | −4.02×10−4 | −47.81 to 39.77×10−4 | 0.857 | 724 |
| 20 | −2.72×10−4 | −54.77 to 49.32×10−4 | 0.918 | 641 |
| Non-Hodgkin’s lymphoma | ||||
| 0 | −0.23×10−3 | −2.62 to 2.17×10−3 | 0.854 | 1976 |
| 10 | −3.04×10−4 | −29.50 to 23.43×10−4 | 0.822 | 1973 |
| 20 | −7.57×10−4 | −42.45 to 27.30×10−4 | 0.670 | 1876 |
| Multiple myeloma | ||||
| 0 | 0.15×10−3 | −1.55 to 1.85×10−3 | 0.858 | 1056 |
| 10 | 1.04×10−4 | −17.61 to 19.70×10−4 | 0.913 | 1054 |
| 20 | −0.52×10−4 | −23.95 to 22.90×10−4 | 0.965 | 955 |
| B-cell malignancy | ||||
| 0 | 5.65×10−4 | −4.74 to 16.03×10−4 | 0.287 | 3785 |
| 10 | 5.42×10−4 | −5.97 to 16.81×10−4 | 0.351 | 3779 |
| 20 | 3.36×10−4 | −11.18 to 17.91 x10−4 | 0.651 | 3517 |